https://www.selleckchem.com/pr....oducts/bms-927711.ht
Purpose To evaluate clinical outcomes and enucleation rates after intravitreal melphalan (IVM) alone and after IVM combined with intravitreal topotecan (IVT) for the treatment of vitreous disease, and to a lesser extent subretinal and retrohyaloid seeds, in patients with retinoblastoma. Study design A retrospective analysis of 77 eyes of 72 consecutive patients. Methods Demographic data, classification of tumors, seed type (dust, sphere or cloud) before injection and at the end of follow-up, injection type (IVM or IVM+IVT), doses of
Like
Comment
Share
